GlobeNewswire Inc | Nov 10, 2020 06:30AM EST

November 10, 2020

-- Established license and strategic collaboration with Roivant Sciences - $60 million in upfront consideration and up to $2 billion in future milestones -- Recognized milestone payment from Genentech for initiation of Phase 1 of RO7297089 -- Ended quarter with 97.3 million of cash, cash equivalents and current financial assets with anticipated cash runway into first half of 2023 -- AFM13 pTCL REDIRECT monotherapy study interim analysis expected during first half of 2021 -- AFM24 (Phase 1/2a) completed cohort 2 and is enrolling and treating patients in cohort 3 -- First patient dosed with preloaded AFM13 allogeneic cord blood-derived natural killer cells at MD Anderson Cancer Center -- Collaborations formed with NKMax America and Artiva Biotherapeutics to accelerate innate cell engager (ICE) / NK cell therapy combinations -- Data from one preclinical and two clinical studies to be presented at upcoming SITC and ASH scientific conferences -- Conference call and webcast scheduled for November 10, 2020 at 8:30 am EST

Heidelberg, Germany, November 10, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the three and nine months ended September 30, 2020 and provided an update on clinical and corporate progress.

We have made significant progress with regards to executing our strategy by advancing the development of our innate cell engagers as monotherapy and in combinations. The partnership with Roivant Sciences broadens our pipeline and advances AFM32 towards clinical development; proceeds from the deal extend our cash runway into 2023, said Dr. Adi Hoess, CEO of Affimed. In addition, we have secured important new NK cell collaborations that broaden the development of our lead therapeutic candidates. As we move ahead, we look forward to reporting on progress of the different programs and generating additional data.

Clinical Stage Program Updates

AFM13 (CD30/CD16A)

-- AFM13-202, a Phase 2 registration-directed study of AFM13 as monotherapy in relapsed or refractory patients with CD30-positive peripheral T-cell lymphoma (pTCL), has recruited the prespecified number of patients for the preplanned interim analysis. Affimed now expects to complete the interim data analysis during the first half of 2021. -- AFM13-104, an investigator sponsored Phase 1 study at MD Anderson Cancer Center evaluating the tolerability and efficacy of AFM13 preloaded cord blood-derived NK (cbNK) cells followed by weekly AFM13 monotherapy in patients with refractory CD30 expressing lymphomas, reported that the first patient has completed the first four-week cycle without noteworthy toxicity and has achieved a partial response according to investigator assessment. The patient is intended to receive a second treatment cycle. -- An oral presentation of the preclinical data from the collaborations with MD Anderson Cancer Center and the University of Washington combining allogeneic cbNK cells preloaded with AFM13 will be presented at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 11th. -- Two abstracts on studies with AFM13 have been accepted for poster presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH). The data presented will be from Columbia Universitys AFM13 study in patients with relapsed or refractory CD30-positive lymphoma with cutaneous presentation and data from the German Hodgkin Study Group study in patients with relapsed or refractory Hodgkin Lymphoma.

AFM24 (EGFR/CD16A)

-- AFM24-101, a Phase 1/2a clinical trial of AFM24, the EGFR/CD16A targeted ICE for patients with EGFR-expressing solid tumors, completed dose cohort 2 and patients are currently being enrolled and treated in cohort 3. -- Affimed entered a clinical collaboration to investigate the combination of AFM24 with NKMax Americas autologous NK cell therapy, SNK01, in a first-in-human proof of concept (POC) trial in patients with EGFR-expressing tumors. The agreement includes an option to broaden the collaboration to include NKMax Americas allogeneic NK cell product. The agreement follows a preclinical collaboration between the two companies that showed synergy between Affimeds ICE molecules and NKMax Americas autologous and cryopreserved allogeneic NK cell products.

Roivant SciencesPartnership

-- Affimed entered into a licensing and strategic collaboration agreement with Roivant Sciences under which the Company will receive $60 million in upfront consideration, including $40 million in cash and pre-funded R&D and $20 million of Roivant equity, up to an additional $2 billion in future milestones and tiered royalties. -- Affimed will grant a license to AFM32 with options for additional ICE molecules directed against targets not included in Affimed's current pipeline. -- Affimed to be responsible for all preclinical work through IND-filing. -- Roivant Sciences to form new subsidiary focused on the development and commercialization of ICE-based therapeutics. -- Affimed retains certain co-promotional rights.

Genentech Partnership

-- The Genentech-partnered, novel BCMA-targeted innate cell engager for the treatment of multiple myeloma is treating patients in a first-in-human Phase I, open-label, multicenter, global dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089. -- The initiation of the Phase 1 study triggered a milestone payment recognized in the third quarter.

Preclinical Pipeline Update

-- AFM28 progressed further in IND-enabling studies and Affimed expects an IND will be filed in the first half of 2022. -- Affimed entered a R&D collaboration with Artiva Biotherapeutics to develop off-the-shelf, cryopreserved, co-vialed allogeneic natural killer (NK) cell therapeutics pre-loaded with its ICE compounds.

Third Quarter 2020 Financial Highlights

(Figures for the third quarter ended September 30, 2020 and 2019 are unaudited.)

As of September 30, 2020, cash, cash equivalents and current financial assets totaled 97.3 million compared to 104.1 million on December 31, 2019. The pro forma cash position of the company as of September 30, 2020, including the $40 million of upfront cash proceeds from the Roivant collaboration, would be 131.5 million. During the quarter, the company received net proceeds of approximately 11.6 million under its at-the-market (ATM) program and a milestone payment from its partnership with Genentech in an undisclosed amount.

Based on its current operating plan and assumptions, Affimed anticipates that its cash, cash equivalents and current financial assets will support operations into the first half of 2023.

Net cash used in operating activities for the quarter ended September 30, 2020 was 3.6 million compared to 11.7 million in the third quarter of 2019.

Total revenue for the third quarter of 2020 was 10.5 million compared with 2.1 million in the third quarter of 2019. Revenue for the third quarter of 2020 and 2019 predominantly relate to the Genentech collaboration (2020: 10.5 million, 2019: 1.9 million). Revenue from the Genentech collaboration in the third quarter 2020 was comprised of revenue recognized for collaborative research services performed during the quarter and the recognition of revenue related to a milestone payment.

R&D expenses for the third quarter of 2020 were 10.1 million compared to 11.7 million in the third quarter of 2019. Expenses in 2020 relate predominantly to our AFM13 and AFM24 clinical programs as well as to our early stage development and discovery activities.

G&A expenses for the third quarter of 2020 were 3.5 million compared to 2.8 million in the third quarter of 2019.

Net loss for the third quarter of 2020 was 6.0 million or 0.07 per common share. For the third quarter of 2019, the companys net loss was 10.9 million or 0.17 per common share.

The weighted number of common shares outstanding for the quarter ended September 30, 2020 were 86.0 million.

Affimed encourages shareholders to also review its 6-K filing for the quarter endedSeptember 30, 2020, as filed with theUnited States Securities and Exchange Commission.

Note on International Financial Reporting Standards (IFRS)

Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. None of the financial statements were prepared in accordance with Generally Accepted Accounting Principles in the United States. Affimed maintains its books and records in Euro.

Conference Call and Webcast Information

Affimed will host a conference call and webcast today, Tuesday, November 10, 2020 at 8:30 a.m. EST to discuss third quarter 2020 financial results and recent corporate developments. The conference call will be available via phone and webcast.

To access the call, please dial +1 (646) 741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference passcode 9847055 approximately 15 minutes prior to the call.

A live audio webcast of the conference call will be available in the Webcasts section on the Investors page of the Affimed website at https://www.affimed.com/investors/webcasts_cp/. A replay of the webcast will be accessible at the same link for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimeds fit-for-purpose ROCK platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential, predict, project, should, will, would and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of AFM13, AFM24, and our other product candidates, the value of our ROCK platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation and the risks, uncertainties and other factors described under the heading Risk Factors in Affimeds filings with the SEC. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Investor RelationsContact

Alexander FudukidisHead of Investor RelationsE-Mail: a.fudukidis@affimed.comTel.: (917) 436-8102

Affimed N.V.Unaudited consolidated statements of comprehensive income / (loss) (in thousand)

For the three months For the nine months ended September 30 ended September 30 2020 2019 2020 2019 Revenue 10,545 2,103 18,614 17,464 Other income ? net 102 49 130 332Research and development expenses (10,101) (11,721) (33,247) (31,253)General and administrative (3,455) (2,790) (9,586) (7,566)expenses Operating income / (loss) (2,909) (12,359) (24,089) (21,023) Finance income / (costs) ? net (3,057) 1,475 (2,404) 1,655 Income / (loss) before tax (5,966) (10,884) (26,493) (19,368) Income taxes 0 0 0 (4) Income / (loss) for the period (5,966) (10,884) (26,493) (19,372) Other comprehensive income /(loss)Items that will not be (139) (555) (129) (531)reclassified to profit or lossEquity investments at fair valueOCI ? net change in fair value Other comprehensive income / (139) (555) (129) (531)(loss) Total comprehensive income / (6,105) (11,439) (26,622) (19,903)(loss) Earnings / (loss) per share in ? (0.07) (0.17) (0.33) (0.31)per share(undiluted = diluted) Weighted number of common shares 86,030,878 62,443,550 80,490,155 62,437,673outstanding

Affimed N.V.Consolidated statements of financial position (in thousand)

September 30, 2020 December 31, 2019 (unaudited) ASSETS Non-current assets Intangible assets 93 137Leasehold improvements and equipment 2,305 2,291Long term financial assets 3,064 3,193Right-of-use assets 1,084 824 6,546 6,445Current assets Cash and cash equivalents 89,656 95,234Financial assets 7,687 8,902Trade and other receivables 2,552 1,482Inventories 410 296Other assets 1,087 0 101,392 105,914TOTAL ASSETS 107,938 112,359 EQUITY AND LIABILITIES Equity Issued capital 883 762Capital reserves 305,301 270,451Fair value reserves 1,833 1,962Accumulated deficit (261,001) (234,508)Total equity 47,016 38,667 Non-current liabilities Borrowings 207 278Contract liabilities 15,203 37,961Lease liabilities 332 272Total non-current liabilities 15,742 38,511 Current liabilities Trade and other payables 8,123 10,674Provisions 479 517Borrowings 1,070 2,105Lease liabilities 779 532Contract liabilities 34,729 21,353Total current liabilities 45,180 35,181 TOTAL EQUITY AND LIABILITIES 107,938 112,359

Affimed N.V.Unaudited consolidated statements of cash flows (in thousand)

(in ? thousand) For the nine months ended September 30 2020 2019Cash flow from operating activities Income / (loss) for the period (26,493) (19,372)Adjustments for the period: - Income taxes 0 4- Depreciation and amortization 821 648- Net gain from disposal of leasehold improvements 0 (9)and equipment- Share based payments 2,348 1,981- Finance income / (costs) ? net 2,404 (1,655) (20,920) (18,403)Change in trade and other receivables (1,174) 458Change in inventories (114) (70)Change in other assets (1,087) (1,104)Change in trade, other payables, provisions and (12,053) (11,727)contract liabilitiesCash used in operating activities (35,348) (30,846)Interest received 299 413Paid interest (81) (180)Net cash used in operating activities (35,130) (30,613) Cash flow from investing activities Purchase of intangible assets (8) (143)Purchase of leasehold improvements and equipment (352) (926)Cash paid for investments in financial assets (8,101) (39,733)Cash received from maturity of financial assets 9,088 38,270Net cash used for investing activities 627 (2,532) Cash flow from financing activities Proceeds from issue of common shares 33,846 26Transaction costs related to issue of common (1,134) 0sharesProceeds from borrowings 0 562Repayment of lease liabilities (386) (299)Repayment of borrowings (1,151) (2,339)Cash flow from financing activities 31,175 (2,050) Exchange-rate related changes of cash and cash (2,250) 361equivalentsNet changes to cash and cash equivalents (3,328) (35,195)Cash and cash equivalents at the beginning of the 95,234 94,829periodCash and cash equivalents at the end of the period 89,656 59,995

Affimed N.V.Unaudited consolidated statements of changes in equity (in thousand)

Issued Capital Accumulated Total capital reserves Fair deficit equity Value reserves

Balance as of January 1, 2019 624 239,055 (202,144) 40,129

2,594 26 26Exercise of share based payment awards Equity-settled share based 1,981 1,981payment awardsLoss for the period (19,372) (19,372)

Other comprehensive income (531)

(531)

624 241,062 2,063 (221,516) 22,233Balance as of September 30, 2019 Balance as of January 1, 2020 762 270,451 1,962 (234,508) 38,667Balance as of January 1, 2020 Issue of common shares 121 32,502 32,623Equity-settled share based 2,348 2,348payment awardsLoss for the period (26,493) (26,493)Other comprehensive income (129) (129)

305,301 1,833 (261,001) 47,016

Balance as of September 30, 2020 883